Pharmaceutical The US medicines cost effectiveness watchdog the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of Japanese drug major Astellas Pharma’s fezolinetant for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, finding that the evidence is not yet adequate to demonstrate a net health benefit to the drug when compared to no pharmacological treatment. 23 January 2023